GLP-1 drugs work by slowing digestion and reducing appetite
Some studies suggest slightly higher rates of GI side effects with tirzepatide at higher doses
Smaller quantities of vitamins, triacylglycerols (TGAs) the dominant lipid components, di- and monoacylglycerols, FAs, short-chain fatty acids (SCFAs), amino acids, and other small bioactive compounds are also evident
The Personalized Compounding Exemption Federal law allows compounding for individual patients when a prescriber determines it's necessary While FDA guidance is more restrictive than the law, it still provides a path for personalized GLP-1 dosages Hims appears to be following the legal framework by offering semaglutide doses different from commercial options The principal legal basis for personalized compounding of GLP-1 drugs can be found in the Food, Drug, and Cosmetics Act (FDCA), specifically in 21 U.S
Tall stature/increased growth velocity ( MC4R monogenic diabetes)